Supplementary Table 17. Comparison of clinicopathologic characteristics between NSCLCs with oncogenic / likely oncogenic *MET* tyrosine kinase domain (TKD) mutations without other concurrent drivers and NSCLCs with *MET* exon 14 alterations in the Caris Life Sciences cohort.

Characteristics	*MET* TKD mutant NSCLC (N=15)	*MET* exon 14 altered NSCLC (N=682)	p
Age			
Median (range)	73 (57-83)	77 (40-89+)	**0.006**
Sex			
Male	10 (66.7%)	301 (44.1%)	0.08
Female	5 (33.3%)	381 (55.9%)	
Smoking status			
Current / Former	6 (100%)	104 (88.1%)	1
Never	0 (0%)	14 (11.9%)	
NA	9	564	
Histology			
Adenocarcinoma	8 (53.3%)	425 (62.3%)	0.9
Squamous Cell Carcinoma	2 (13.3%)	78 (11.4%)	
Adenosquamous	1 (6.7%)	25 (3.7%)	
Sarcomatoid	0 (0.0%)	24 (3.5%)	
Large Cell Carcinoma	0 (0.0%)	1 (0.1%)	
Other/Unclear Histology	4 (26.7%)	129 (18.9%)	
PD-L1 TPS			
< 1%	5 (35.7%)	127 (19.3%)	0.1
1-49%	1 (7.2%)	190 (28.9%)	
≥ 50%	8 (57.1%)	341 (51.8%)	
NA	1	24	
Concurred *MET* amplification			
Yes	1 (6.6%)	20 (2.9%)	0.37
No	14 (93.4%)	662 (97.1%)	
TMB mut/Mb*			
Median (range)	12.5 (1-27)	4 (0-24)	**< 0.0001**

Abbreviations: TMB, tumor mutation burden; TPS, tumor proportion score; NA, not available.
*5 cases had TMB <5 , 7 cases had 10 <TMB< 20, 2 cases had TMB > 20, in 1 case TMB was not available.